{"id":1062,"date":"2025-03-03T06:09:50","date_gmt":"2025-03-03T06:09:50","guid":{"rendered":"https:\/\/www.cd-bioparticles.net\/blog\/?p=1062"},"modified":"2025-03-03T06:09:50","modified_gmt":"2025-03-03T06:09:50","slug":"breaking-the-blood-brain-barrier-liposome-targeted-delivery-technology-reshaping-the-treatment-landscape-of-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.cd-bioparticles.net\/blog\/breaking-the-blood-brain-barrier-liposome-targeted-delivery-technology-reshaping-the-treatment-landscape-of-alzheimers-disease\/","title":{"rendered":"Breaking the Blood-Brain Barrier: Liposome Targeted Delivery Technology Reshaping the Treatment Landscape of Alzheimer’s Disease"},"content":{"rendered":"

Although the relationship between \u03b2-amyloid protein deposition and the formation of hyperphosphorylated Tau protein and neurofibrillary tangles and Alzheimer’s disease has been elucidated, current treatments can only alleviate symptoms but cannot cure it. Researchers and clinicians commonly aim to identify effective treatments that target disease root causes. The advanced drug delivery system known as liposomes has demonstrated substantial potential for treating Alzheimer’s Disease in recent scientific developments. These systems allow loading multiple active substances for targeted delivery while enhancing targeting and BBB penetration through surface modification to ensure precise drug delivery to specific brain locations. Through surface modification liposomes can be engineered to selectively attach to A\u03b2 for removal and block Tau protein aggregation while targeting other Alzheimer’s disease (AD) markers. This article focuses on presenting the current advancements of liposome technology for Alzheimer’s Disease treatment while examining their benefits as a delivery system and pointing out existing challenges along with future research paths.<\/p>\r\n

\"Figure
Figure 1. Application of liposomes in the treatment of Alzheimer’s disease.<\/figcaption><\/figure>\r\n\r\n

Structure and Modification of Liposomes<\/strong><\/p>\r\n\r\n\r\n\r\n

Basic Structure and Composition<\/p>\r\n\r\n\r\n\r\n

Liposomes comprise one or multiple enclosed microvesicles constructed from phospholipid bilayers leading to the formation of unilamellar liposomes and both multilamellar liposomes. The single phospholipid bilayer of unilamellar liposomes with small diameters enables them to carry both small molecule drugs and large biomacromolecules. Multilamellar liposomes (MLV) consist of multiple phospholipid bilayers and measure from 100 to 1000 nanometers in size. The structural organization shows multiple layers similar to an onion’s structure. Each layer of the multilamellar liposome structure can store water-soluble drugs making it ideal for delivering multiple medications in combination therapies. Phospholipids and cholesterol build liposomes along with additional supporting components.<\/p>\r\n\r\n\r\n\r\n

Surface Modification<\/p>\r\n\r\n\r\n\r\n

A vital technical technique to modify liposomes involves attaching molecules to their surface. PEGylation remains the most important liposome surface modification method because it improves liposome stability in the bloodstream while reducing reticuloendothelial system clearance thereby prolonging their circulation time. The intentional modification of liposome surfaces with targeting ligands like antibodies allows for their active attachment to cell surface receptors which enables targeted delivery. Scientists can develop drug release systems by connecting liposomes with thermosensitive or pH-sensitive materials which activate drug discharge upon changes in environmental temperature or pH levels.<\/p>\r\n\r\n\r\n\r\n

Advantages of Liposomes in Drug Delivery<\/strong><\/p>\r\n\r\n\r\n\r\n

Liposomes can provide protection for hydrophilic drugs and make them more stable in the body; while for hydrophobic drugs, liposomes can improve their water solubility and improve their distribution and absorption in the body. This will increase the bioavailability of drugs in the body. Liposomes provide sustained drug release alongside controlled drug delivery while supporting stable drug concentrations and extended drug action duration for treatments needing long-term effectiveness. Liposomes stand out as advanced drug delivery systems because their distinct structure and preparation adaptability deliver significant benefits in biocompatibility, sustained release, drug targeting and protection which open new treatment possibilities for numerous diseases particularly where biological barrier crossing or precise drug delivery is required thus showing extensive application potential.<\/p>\r\n\r\n\r\n\r\n

Liposomes have Emerged as a Therapeutic Tool in Alzheimer’s Disease Treatment<\/strong><\/p>\r\n\r\n\r\n\r\n

The targeted treatment approach for Alzheimer’s Disease reveals high potential for liposomes and modified liposomes. The modification of liposomes includes adding molecules to their surface and encapsulating drugs within the vesicle’s water core or lipid bilayer while also modifying specific ligands or antibodies to target brain lesions in AD patients like A\u03b2 plaques or Tau protein aggregation sites for accurate drug delivery that enhances therapeutic effects and minimizes normal tissue side effects. A single PEG modification enhances both water solubility and stability of drugs while PEG-linked peptides and antibodies alongside glutathione (GSH), surface antibodies, lactoferrin, glucose, wheat germ agglutinin, and transferrin (Tf) aid drug crossing of the BBB and phosphatidic acid, PEG-curcumin, lipophilic peptides, lipophilic drugs, hydrophilic peptides, hydrophilic drugs, and nucleic acids actively participate in targeted AD treatment forming an effective therapy strategy. These innovative technologies and modifications enhance drugs’ stability and bioavailability while facilitating their penetration through the BBB and enabling effective brain delivery to produce a synergistic therapeutic impact. Tab. 1 Application of liposomes in the treatment of Alzheimer\u2019s disease<\/strong><\/p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n
Preparation<\/strong><\/td>\r\nModification<\/strong><\/td>\r\nDrug Loaded<\/strong><\/td>\r\nTherapeutic Target<\/strong><\/td>\r\nTherapeutic Effect<\/strong><\/td>\r\n<\/tr>\r\n<\/thead>\r\n
PEGylated liposomes with DMPC and EYPC<\/td>\r\nGSH<\/td>\r\nVHH-pa2H<\/td>\r\nBrain A\u03b2<\/td>\r\nImproved targeting and increased residence time of VHH-pa2H in the brain<\/td>\r\n<\/tr>\r\n
Cholesterol linked with different chain-length PEG at the C-6 position of glucose<\/td>\r\nGLU<\/td>\r\n–<\/td>\r\nBrain<\/td>\r\nGLU modification significantly enhances the brain-targeted delivery of liposomes<\/td>\r\n<\/tr>\r\n
Tf-modified liposomes loaded with GA<\/td>\r\nTf<\/td>\r\nGA<\/td>\r\nBrain A\u03b2<\/td>\r\nTf modification improves BBB penetration, slow and sustained GA release, effectively inhibiting A\u03b2 aggregation<\/td>\r\n<\/tr>\r\n
ApoE3-reconstructed ApoE3-rHDL with DMPC<\/td>\r\nApoE<\/td>\r\n\u03b1-M<\/td>\r\nBrain A\u03b2<\/td>\r\nReduced A\u03b2 deposition, promotes microglia-mediated A\u03b2 disaggregation, improves memory defects<\/td>\r\n<\/tr>\r\n
DSPC, cholesterol, and DPS-PEG2000-CURC mixed, surface-conjugated with MAb<\/td>\r\nMAb<\/td>\r\nCURC<\/td>\r\nBrain A\u03b2<\/td>\r\nTargets amyloid protein deposits, delays A\u03b2 aggregation, significantly increases BBB cellular model uptake<\/td>\r\n<\/tr>\r\n
MAN and TAT-modified liposomes encapsulating PEI and miR-195 complex<\/td>\r\nMAN, TAT<\/td>\r\nmiR-195<\/td>\r\nBrain A\u03b2<\/td>\r\nEnhances BBB penetration, reduces instability and toxicity<\/td>\r\n<\/tr>\r\n
Hybrid nanovesicles of exosomes and siBACE1\/pTREM2-loaded liposomes<\/td>\r\nExosome, Ang2<\/td>\r\nsiBACE1, pTREM2<\/td>\r\nBACE1, TREM2<\/td>\r\nEfficient BBB crossing, modulates microglia phenotype, reduces A\u03b2 accumulation, prevents neuroinflammation, improves cognitive impairment<\/td>\r\n<\/tr>\r\n
DSPC, cholesterol, DSPE-PEG-COOH mixed, conjugated with CP-2 and Cy5<\/td>\r\nCP-2<\/td>\r\n–<\/td>\r\nA\u03b2Os<\/td>\r\nInhibits A\u03b2 aggregation and reduces its toxicity, improves cognitive function<\/td>\r\n<\/tr>\r\n
PA incorporated liposomes, surface-conjugated with Tf and Pep63<\/td>\r\nTf<\/td>\r\nPep63<\/td>\r\nHippocampus A\u03b2<\/td>\r\nReduces hippocampal A\u03b2 load, inhibits EphB2-A\u03b2Os binding, restores NMDA receptor trafficking<\/td>\r\n<\/tr>\r\n
TPPB-14-modified liposomes loaded with \u03b1-tocopherol and donepezil hydrochloride<\/td>\r\nTPPB-14<\/td>\r\n\u03b1-tocopherol, donepezil hydrochloride<\/td>\r\nHippocampus A\u03b2<\/td>\r\nReduces A\u03b2 plaque quantity and formation speed, improves memory function<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n

Single-Target Ligand Modification<\/strong><\/p>\r\n

Glutathione The naturally occurring tripeptide GSH consists of glutamic acid, cysteine, and glycine. The molecule serves as a crucial antioxidant within cellular structures and assumes a significant function in numerous physiological functions. GSH-modified liposomes represent a drug delivery technology that takes advantage of GSH’s unique properties to improve delivery efficiency. Research teams developed GSH-PEG liposomes for transporting anti-amyloid single-domain antibody fragments known as VHH-pa2H through the BBB into the brain. Researchers prepared two formulations of GSH-PEG liposomes which used dimyristoylphosphatidylcholine (DMPC) and egg yolk phosphatidylcholine (EYPC) and encapsulated VHH-pa2H within them before labeling the antibody fragment with indium-111 to study its biodistribution. Encapsulation of VHH-pa2H in GSH-PEGEYPC liposomes resulted in a 4 times higher concentration in the brains of AD mouse models compared to free VHH-pa2H and showed enhanced retention and targeting of antibody fragments. Glucose Glucose functions as the brain’s primary energy source while the brain itself lacks the ability to produce glucose. The movement of glucose through the brain capillary walls requires the glucose transporter (Glut) present on the endothelial cells. The glucose-modified liposomes technology improves liposome functionality through their ability to attach to glucose molecules. Glut expression levels in the brain and its high transport efficiency make it possible for glucose modification to enhance liposomal brain targeting which then delivers drugs more effectively to AD patient brains for lesion area treatment. Glucose modification enhances liposome biocompatibility and stability which results in prolonged drug circulation time throughout the body while reducing immune system reactions. Transferrin Transferrin exists abundantly within the bloodstream. Transferrin functions as an iron ion transporter and possesses its specific transferrin receptor (TfR) in numerous cell types. The receptor shows high expression levels in brain cells particularly on BBB endothelial cells. Transferrin-modified liposomes enhance drug delivery to the brain by binding to TfR which enables drugs to cross the BBB and become essential tools for treating central nervous system diseases such as AD. Apolipoprotein E Apolipoprotein E ApoE functions as a protein that occurs throughout the entire body. Apolipoprotein E plays a critical function in lipid metabolism and cholesterol transport while showing strong connections to AD pathogenesis. Among the ApoE variants linked to Alzheimer’s disease risk, ApoE4 stands out by causing brain A\u03b2 aggregation and escalating AD susceptibility. The targeting ligands modification process utilizes ApoE to enhance liposome delivery to brain lesion areas in AD patients by facilitating BBB crossing through low-density lipoprotein receptor binding and enabling controlled drug release in response to specific lesion conditions.<\/p>\r\n

Multi-Target Liposomes<\/strong><\/p>\r\n

Liposomes with Curcumin Derivatives and Brain-Targeting Functions The natural polyphenol compound Curcumin (CURC) originates from turmeric rhizomes. CURC demonstrates potent antioxidant properties that enable it to eliminate free radicals thereby protecting neurons from oxidative stress-induced damage. CURC and its derivatives attach to A\u03b2 peptides which disrupts their aggregation resulting in fewer A\u03b2 plaque formations. The water solubility and bioavailability of CURC remain low when not encapsulated. Encapsulation of CURC in liposomes improves its solubility and stability while increasing bioavailability and enabling targeted delivery which enhances its therapeutic efficacy. The research team created brain-specific multifunctional nanoliposomes DPS-PEG2000-CURC NLs containing CURC derivatives to target A\u03b2 deposits in Alzheimer’s disease brains. PEG modification sustains liposomes in the bloodstream longer and improves their stability at the same time CURC modification allows liposomes to block A\u03b2 aggregation. The researchers increased nanoliposomes’ BBB penetration capability by attaching a BBB transport mediator anti-TfR monoclonal antibody (MAb) to their surface. The multifunctional nanoliposomes exhibited both anti-A\u03b2 aggregation effects and successful BBB crossing abilities in experimental results. Bionic Exosome-Liposome Hybrid Nanovesicles Scientists designed a ROS-responsive bionic nanovesicle system called TSEL: The researchers began by preparing a liposome film from a lipid mixture via rotary evaporation which allowed the loading of pTREM2 and siBACE1 into liposomes’ hydrophilic space through a hydrated lipid film before extracting exosomes from MSC supernatants using ultracentrifugation and combining them with drug-loaded liposomes to form hybrid nanovesicles. Nanovesicles combine exosome homing ability with Ang2 assistance to cross the BBB and concentrate in the AD lesion area. The expression of TREM2 can switch microglia from M1 pro-inflammatory state to M2 anti-inflammatory state which restores A\u03b2 phagocytosis and neurorepair functions. The therapeutic effect of AD treatment improves when siRNA reduces A\u03b2 plaque formation through BACE1 gene knockdown.<\/p>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n
Product Name<\/td>\r\nCatalog<\/td>\r\nPrice<\/td>\r\n<\/tr>\r\n
Clipos\u2122 Cardiolipin Lipids (CL) Liposomes<\/a><\/td>\r\nCDECAR-1629<\/td>\r\n$2,100<\/td>\r\n<\/tr>\r\n
Clipos\u2122 Cardiolipin Lipids (CL) Liposomes<\/a><\/td>\r\nCDECAR-1631<\/td>\r\n$2,100<\/td>\r\n<\/tr>\r\n
Clipos\u2122 Cardiolipin Lipids (CL) Liposomes<\/a><\/td>\r\nCDECAR-1637<\/td>\r\n$2,100<\/td>\r\n<\/tr>\r\n
Clipos\u2122 Phosphatidylglycerol (PG) Liposomes<\/a><\/td>\r\nCDECPG-1655<\/td>\r\n$2,100<\/td>\r\n<\/tr>\r\n
Clipos\u2122 Phosphatidylglycerol (PG) Liposomes<\/a><\/td>\r\nCDECPG-1660<\/td>\r\n$2,100<\/td>\r\n<\/tr>\r\n
Clipos\u2122 Phosphatidylglycerol (PG) Liposomes<\/a><\/td>\r\nCDECPG-1662<\/td>\r\n$2,100<\/td>\r\n<\/tr>\r\n
Clipos\u2122 Diether Phosphatidylcholine (PC) Liposomes<\/a><\/td>\r\nCDECDEE-1616<\/td>\r\n$2,100<\/td>\r\n<\/tr>\r\n
Clipos\u2122 Saturated Phosphatidylcholine (PC) Liposomes<\/a><\/td>\r\nCDECHP-1557<\/td>\r\n$2,100<\/td>\r\n<\/tr>\r\n
Clipos\u2122 Natural Phosphatidylcholine (PC) Lipid Liposomes<\/a><\/td>\r\nCDECPC-1594<\/td>\r\n$2,450<\/td>\r\n<\/tr>\r\n
Clipos\u2122 DOTAP Liposomes<\/a><\/td>\r\nCDECDEP-1646<\/td>\r\n$2,100<\/td>\r\n<\/tr>\r\n
Clipos\u2122 DOTAP Liposomes<\/a><\/td>\r\nCDECDEP-1652<\/td>\r\n$2,100<\/td>\r\n<\/tr>\r\n
Clipos\u2122 DOTAP Liposomes<\/a><\/td>\r\nCDECDEP-1654<\/td>\r\n$2,100<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>","protected":false},"excerpt":{"rendered":"

Although the relationship between \u03b2-amyloid protein deposition and the formation of hyperphosphorylated Tau protein and neurofibrillary tangles and Alzheimer’s disease has been elucidated, current treatments can only alleviate symptoms but cannot cure it. Researchers and clinicians commonly aim to identify effective treatments that target disease root causes. The advanced drug delivery system known as liposomes has demonstrated substantial potential for treating Alzheimer’s Disease in recent scientific developments. These systems allow loading multiple active substances for targeted delivery while enhancing targeting and BBB penetration through surface modification to ensure precise drug delivery to specific brain locations. Through surface modification liposomes can be engineered to selectively attach to A\u03b2 for removal and block Tau protein aggregation while targeting other Alzheimer’s disease (AD) markers. This article focuses on presenting the current advancements of liposome technology for Alzheimer’s Disease treatment while examining their benefits as a delivery system and pointing out existing challenges along with future research paths. Structure and Modification of Liposomes Basic Structure and Composition Liposomes comprise one or multiple enclosed microvesicles constructed from phospholipid bilayers leading to the formation of unilamellar liposomes and both multilamellar liposomes. The single phospholipid bilayer of unilamellar liposomes with small diameters enables them to carry both small molecule drugs and large biomacromolecules. Multilamellar liposomes (MLV) consist of multiple phospholipid bilayers and measure from 100 to 1000 nanometers in size. The structural organization shows multiple layers similar to an onion’s structure. Each layer of the multilamellar liposome structure can store water-soluble drugs making it ideal for delivering multiple medications in combination therapies. Phospholipids and cholesterol build liposomes along with additional supporting components. Surface Modification A vital technical technique to modify liposomes involves attaching molecules to their surface. PEGylation remains the most important liposome surface modification method because it improves liposome stability in the bloodstream while reducing reticuloendothelial system clearance thereby prolonging their circulation time. The intentional modification of liposome surfaces with targeting ligands like antibodies allows for their active attachment to cell surface receptors which enables targeted delivery. Scientists can develop drug release systems by connecting liposomes with thermosensitive or pH-sensitive materials which activate drug discharge upon changes in environmental temperature or pH levels. Advantages of Liposomes in Drug Delivery Liposomes can provide protection for hydrophilic drugs and make them more stable in the body; while for hydrophobic drugs, liposomes can improve their water solubility and improve their distribution and absorption in the body. This will increase the bioavailability of drugs in the body. Liposomes provide sustained drug release alongside controlled drug delivery while supporting stable drug concentrations and extended drug action duration for treatments needing long-term effectiveness. Liposomes stand out as advanced drug delivery systems because their distinct structure and preparation adaptability deliver significant benefits in biocompatibility, sustained release, drug targeting and protection which open new treatment possibilities for numerous diseases particularly where biological barrier crossing or precise drug delivery is required thus showing extensive application potential. Liposomes have Emerged as a Therapeutic Tool in Alzheimer’s Disease Treatment The targeted treatment approach for Alzheimer’s Disease reveals high potential for liposomes and modified liposomes. The modification of liposomes includes adding molecules to their surface and encapsulating drugs within the vesicle’s water core or lipid bilayer while also modifying specific ligands or antibodies to target brain lesions in AD patients like A\u03b2 plaques or Tau protein aggregation sites for accurate drug delivery that enhances therapeutic effects and minimizes normal tissue side effects. A single PEG modification enhances both water solubility and stability of drugs while PEG-linked peptides and antibodies alongside glutathione (GSH), surface antibodies, lactoferrin, glucose, wheat germ agglutinin, and transferrin (Tf) aid drug crossing of the BBB and phosphatidic acid, PEG-curcumin, lipophilic peptides, lipophilic drugs, hydrophilic peptides, hydrophilic drugs, and nucleic acids actively participate in targeted AD treatment forming an effective therapy strategy. These innovative technologies and modifications enhance drugs’ stability and bioavailability while facilitating their penetration through the BBB and enabling effective brain delivery to produce a synergistic therapeutic impact. Tab. 1 Application of liposomes in the treatment of Alzheimer\u2019s disease Preparation Modification Drug Loaded Therapeutic Target Therapeutic Effect PEGylated liposomes with DMPC and EYPC GSH VHH-pa2H Brain A\u03b2 Improved targeting and increased residence time of VHH-pa2H in the brain Cholesterol linked with different chain-length PEG at the C-6 position of glucose GLU – Brain GLU modification significantly enhances the brain-targeted delivery of liposomes Tf-modified liposomes loaded with GA Tf GA Brain A\u03b2 Tf modification improves BBB penetration, slow and sustained GA release, effectively inhibiting A\u03b2 aggregation ApoE3-reconstructed ApoE3-rHDL with DMPC ApoE \u03b1-M Brain A\u03b2 Reduced A\u03b2 deposition, promotes microglia-mediated A\u03b2 disaggregation, improves memory defects DSPC, cholesterol, and DPS-PEG2000-CURC mixed, surface-conjugated with MAb MAb CURC Brain A\u03b2 Targets amyloid protein deposits, delays A\u03b2 aggregation, significantly increases BBB cellular model uptake MAN and TAT-modified liposomes encapsulating PEI and miR-195 complex MAN, TAT miR-195 Brain A\u03b2 Enhances BBB penetration, reduces instability and toxicity Hybrid nanovesicles of exosomes and siBACE1\/pTREM2-loaded liposomes Exosome, Ang2 siBACE1, pTREM2 BACE1, TREM2 Efficient BBB crossing, modulates microglia phenotype, reduces A\u03b2 accumulation, prevents neuroinflammation, improves cognitive impairment DSPC, cholesterol, DSPE-PEG-COOH mixed, conjugated with CP-2 and Cy5 CP-2 – A\u03b2Os Inhibits A\u03b2 aggregation and reduces its toxicity, improves cognitive function PA incorporated liposomes, surface-conjugated with Tf and Pep63 Tf Pep63 Hippocampus A\u03b2 Reduces hippocampal A\u03b2 load, inhibits EphB2-A\u03b2Os binding, restores NMDA receptor trafficking TPPB-14-modified liposomes loaded with \u03b1-tocopherol and donepezil hydrochloride TPPB-14 \u03b1-tocopherol, donepezil hydrochloride Hippocampus A\u03b2 Reduces A\u03b2 plaque quantity and formation speed, improves memory function Single-Target Ligand Modification Glutathione The naturally occurring tripeptide GSH consists of glutamic acid, cysteine, and glycine. The molecule serves as a crucial antioxidant within cellular structures and assumes a significant function in numerous physiological functions. GSH-modified liposomes represent a drug delivery technology that takes advantage of GSH’s unique properties to improve delivery efficiency. Research teams developed GSH-PEG liposomes for transporting anti-amyloid single-domain antibody fragments known as VHH-pa2H through the BBB into the brain. Researchers prepared two formulations of GSH-PEG liposomes which used dimyristoylphosphatidylcholine (DMPC) and egg yolk phosphatidylcholine (EYPC) and encapsulated VHH-pa2H within them before labeling the antibody fragment with indium-111 to study its biodistribution. Encapsulation of VHH-pa2H in GSH-PEGEYPC liposomes resulted in a 4 times higher concentration in the brains of AD mouse models compared to free VHH-pa2H and showed enhanced retention and targeting of antibody fragments. Glucose Glucose functions as the brain’s primary energy source while the brain itself lacks the ability to produce glucose. The movement of glucose through the brain capillary walls requires the glucose transporter (Glut) present on the endothelial cells. The glucose-modified liposomes technology improves liposome functionality through their ability to attach to glucose molecules. Glut expression levels in the brain and its high transport efficiency make it possible for glucose modification to enhance liposomal brain targeting which then delivers drugs more effectively to AD patient brains for lesion area treatment. Glucose modification enhances liposome biocompatibility and stability which results in prolonged drug circulation time throughout the body while reducing immune system reactions. Transferrin Transferrin exists abundantly within the bloodstream. Transferrin functions as an iron ion transporter and possesses its specific transferrin receptor (TfR) in numerous cell types. The receptor shows high expression levels in brain cells particularly on BBB endothelial cells. Transferrin-modified liposomes enhance drug delivery to the brain by binding to TfR which enables drugs to cross the BBB and become essential tools for treating central nervous system diseases such as AD. Apolipoprotein E Apolipoprotein E ApoE functions as a protein that occurs throughout the entire body. Apolipoprotein E plays a critical function in lipid metabolism and cholesterol transport while showing strong connections to AD pathogenesis. Among the ApoE variants linked to Alzheimer’s disease risk, ApoE4 stands out by causing brain A\u03b2 aggregation and escalating AD susceptibility. The targeting ligands modification process utilizes ApoE to enhance liposome delivery to brain lesion areas in AD patients by facilitating BBB crossing through low-density lipoprotein receptor binding and enabling controlled drug release in response to specific lesion conditions. Multi-Target Liposomes Liposomes with Curcumin Derivatives and Brain-Targeting Functions The natural polyphenol compound Curcumin (CURC) originates from turmeric rhizomes. CURC demonstrates potent antioxidant properties that enable it to eliminate free radicals thereby protecting neurons from oxidative stress-induced damage. CURC and its derivatives attach to A\u03b2 peptides which disrupts their aggregation resulting in fewer A\u03b2 plaque formations. The water solubility and bioavailability of CURC remain low when not encapsulated. Encapsulation of CURC in liposomes improves its solubility and stability while increasing bioavailability and enabling targeted delivery which enhances its therapeutic efficacy. The research team created brain-specific multifunctional nanoliposomes DPS-PEG2000-CURC NLs containing CURC derivatives to target A\u03b2 deposits in Alzheimer’s disease brains. PEG modification sustains liposomes in the bloodstream longer and improves their stability at the same time CURC modification allows liposomes to block A\u03b2 aggregation. The researchers increased nanoliposomes’ BBB penetration capability by attaching a BBB transport mediator anti-TfR monoclonal antibody (MAb) to their surface. The multifunctional nanoliposomes exhibited both anti-A\u03b2 aggregation effects and successful BBB crossing abilities in experimental results. Bionic Exosome-Liposome Hybrid Nanovesicles Scientists designed a ROS-responsive bionic nanovesicle system called TSEL: The researchers began by preparing a liposome film from a lipid mixture via rotary evaporation which allowed the loading of pTREM2 and siBACE1 into liposomes’ hydrophilic space through a hydrated lipid film before extracting exosomes from MSC supernatants using ultracentrifugation and combining them with drug-loaded liposomes to form hybrid nanovesicles. Nanovesicles combine exosome homing ability with Ang2 assistance to cross the BBB and concentrate in the AD lesion area. The expression of TREM2 can switch microglia from M1 pro-inflammatory state to M2 anti-inflammatory state which restores A\u03b2 phagocytosis and neurorepair functions. The therapeutic effect of AD treatment improves when siRNA reduces A\u03b2 plaque formation through BACE1 gene knockdown. Product Name Catalog Price Clipos\u2122 Cardiolipin Lipids (CL) Liposomes CDECAR-1629 $2,100 Clipos\u2122 Cardiolipin Lipids (CL) Liposomes CDECAR-1631 $2,100 Clipos\u2122 Cardiolipin Lipids (CL) Liposomes CDECAR-1637 $2,100 Clipos\u2122 Phosphatidylglycerol (PG) Liposomes CDECPG-1655 $2,100 Clipos\u2122 Phosphatidylglycerol (PG) Liposomes CDECPG-1660 $2,100 Clipos\u2122 Phosphatidylglycerol (PG) Liposomes CDECPG-1662 $2,100 Clipos\u2122 Diether Phosphatidylcholine (PC) Liposomes CDECDEE-1616 $2,100 Clipos\u2122 Saturated Phosphatidylcholine (PC) Liposomes CDECHP-1557 $2,100 Clipos\u2122 Natural Phosphatidylcholine (PC) Lipid Liposomes CDECPC-1594 $2,450 Clipos\u2122 DOTAP Liposomes CDECDEP-1646 $2,100 Clipos\u2122 DOTAP Liposomes CDECDEP-1652 $2,100 Clipos\u2122 DOTAP Liposomes CDECDEP-1654 $2,100<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[23],"class_list":["post-1062","post","type-post","status-publish","format-standard","hentry","category-liposomes","tag-introduction"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/posts\/1062"}],"collection":[{"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/comments?post=1062"}],"version-history":[{"count":3,"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/posts\/1062\/revisions"}],"predecessor-version":[{"id":1066,"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/posts\/1062\/revisions\/1066"}],"wp:attachment":[{"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/media?parent=1062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/categories?post=1062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/tags?post=1062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}